India vs Sur: The number of people with susceptibility test result for rifampicin
India
673,008
in 2021
Sur
67
in 2021
India rank
1st
Sur rank
2nd
The number of people with susceptibility test result for rifampicin over time
- India
- Sur
How they compare
India currently reports 673,008 against 67 in Sur, a difference of 672,941.
Across all 5 years both countries report, India has been ahead every year.
India ranks 1st and Sur ranks 2nd of 155 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 444,726 | 81.33 | 444,645 | India |
| 2020s | 615,232 | 66.5 | 615,166 | India |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, India or Sur?
- India, at 673,008 against 67 in Sur as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between India and Sur?
- 672,941, with India ahead.
- How many years of comparable data are there for India and Sur?
- 5 years are reported by both, from 2017 to 2021.
- How do India and Sur rank globally for the number of people with susceptibility test result for rifampicin?
- India ranks 1st and Sur ranks 2nd of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.